{"id":"W3041197920","doi":"10.1016/j.annonc.2020.04.078","title":"LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Sorafenib; Nivolumab; Tolerability; Internal medicine; Hazard ratio; Hepatocellular carcinoma; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Adverse effect; Phases of clinical research; Confidence interval; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005820586,0.0001938947,0.000760767,0.0001709862,0.0001856448,0.0007438092,0.0002224206,0.0003234541,0.001711844],"category_scores_gemma":[0.001061916,0.0001034358,0.001204838,0.0002175399,0.0001484034,0.0004622408,0.0003263601,0.0007691731,0.0002769135],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006929259,"about_ca_system_score_gemma":0.0005344763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001408276,"about_ca_topic_score_gemma":0.003730814,"domain_scores_codex":[0.9998067,0.00005356848,0.0000174438,0.00004144263,0.00002645974,0.00005439577],"domain_scores_gemma":[0.9993771,0.000109948,0.0001979459,0.00004282432,0.00003064108,0.0002416149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4171497,0.00286352,0.3403235,0.0006904412,0.004733522,0.0002528306,0.0001546359,0.003445171,0.008044659,0.0003668026,0.006659668,0.2153155],"study_design_scores_gemma":[0.03065228,0.06514511,0.8796067,0.0002679356,0.006336587,0.0007966201,0.0002433234,0.006169794,0.004042491,0.0007658435,0.005851446,0.0001218018],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995611,0.002281336,0.0000959121,0.0002821302,0.00006792604,0.00002482112,0.0007239911,0.00002603252,0.0008868888],"genre_scores_gemma":[0.9978648,0.0003919916,0.0001060464,0.0001935575,0.00005242639,0.00002579731,0.0009741525,0.000004035097,0.0003871801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001711844,"threshold_uncertainty_score":0.005726695,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1101767701585137,"score_gpt":0.317012982306879,"score_spread":0.2068362121483653,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}